KR20240161970A - 항-par2 항체 - Google Patents

항-par2 항체 Download PDF

Info

Publication number
KR20240161970A
KR20240161970A KR1020247034959A KR20247034959A KR20240161970A KR 20240161970 A KR20240161970 A KR 20240161970A KR 1020247034959 A KR1020247034959 A KR 1020247034959A KR 20247034959 A KR20247034959 A KR 20247034959A KR 20240161970 A KR20240161970 A KR 20240161970A
Authority
KR
South Korea
Prior art keywords
amino acid
seq
acid sequence
antibody
par2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247034959A
Other languages
English (en)
Korean (ko)
Inventor
캐서린 허칭스
그렉 오스본
올리버 슈렌커
크르지스스토프 오크라사
안드레이 주코프
아니카 슈미트
알렉산드라 크라우스
도로테 륄레
Original Assignee
넥세라 파마 유케이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 넥세라 파마 유케이 리미티드 filed Critical 넥세라 파마 유케이 리미티드
Publication of KR20240161970A publication Critical patent/KR20240161970A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247034959A 2022-03-24 2023-03-24 항-par2 항체 Pending KR20240161970A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2204159.4A GB202204159D0 (en) 2022-03-24 2022-03-24 Antibodies
GB2204159.4 2022-03-24
PCT/GB2023/050760 WO2023180767A1 (en) 2022-03-24 2023-03-24 Anti-par2 antibodies

Publications (1)

Publication Number Publication Date
KR20240161970A true KR20240161970A (ko) 2024-11-13

Family

ID=81449405

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247034959A Pending KR20240161970A (ko) 2022-03-24 2023-03-24 항-par2 항체

Country Status (10)

Country Link
US (1) US20250313621A1 (https=)
EP (1) EP4499694A1 (https=)
JP (1) JP2025510815A (https=)
KR (1) KR20240161970A (https=)
CN (1) CN119137152A (https=)
AU (1) AU2023238937A1 (https=)
CA (1) CA3246035A1 (https=)
GB (1) GB202204159D0 (https=)
IL (1) IL315704A (https=)
WO (1) WO2023180767A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024255639A1 (en) * 2023-04-14 2025-10-02 Triveni Bio, Inc. Dual inhibitor trypsin antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
US7888482B2 (en) * 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
MX2019010802A (es) 2017-03-16 2019-10-30 Medimmune Ltd Anticuerpos anti-par2 y usos de los mismos.
SMT202500106T1 (it) * 2020-08-18 2025-05-12 Cephalon Llc Anticorpi anti-par-2 e loro metodi d'uso

Also Published As

Publication number Publication date
WO2023180767A1 (en) 2023-09-28
CA3246035A1 (en) 2023-09-28
CN119137152A (zh) 2024-12-13
JP2025510815A (ja) 2025-04-15
US20250313621A1 (en) 2025-10-09
GB202204159D0 (en) 2022-05-11
AU2023238937A1 (en) 2024-10-31
EP4499694A1 (en) 2025-02-05
IL315704A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
JP6872069B2 (ja) ＦｃＲＨ５に対するヒト化親和性成熟抗体及び使用方法
KR102536145B1 (ko) 항-pd-1 항체 및 이의 용도
CN107108747B (zh) 具有共同轻链的双特异性抗体或抗体混合物
JP2026062933A (ja) Ｃｄ７３特異的結合分子及びその使用
JP2023531989A (ja) Ｃｃｒ８抗体及びその使用
JP2022084670A (ja) 抗ｈｌａ－ｇ特異的抗体
TW202204397A (zh) 對冠狀病毒s蛋白質具特異性之化合物及其用途
AU2017256786B2 (en) Binding molecules specific for FcγGamma RIIA and uses thereof
US20250179172A1 (en) Cd5 antibody and use thereof
JP2021503280A (ja) 免疫グロブリン様転写産物３（ｉｌｔ３）に特異的な抗体およびその使用
US12378311B2 (en) Anti-MARCO antibodies and uses thereof
JP2022547850A (ja) 抗ｔｉｇｉｔ免疫阻害剤及び応用
EP4428156A1 (en) Anti-bcma nanobody and use thereof
KR20230015957A (ko) 이중특이적 항체 및 이의 용도
KR20240161970A (ko) 항-par2 항체
JP2025503707A (ja) ガレクチン－１０抗体
JP2024521904A (ja) 抗ｔｒｅｍ－１抗体
JP2023518000A (ja) Ｒｏｒ２をターゲティングする、親和性成熟ヒト化結合性ドメイン
CN119390838B (zh) 一种靶向ccr7的纳米抗体及其制备与应用
EP4527851A1 (en) Bispecific antibodies binding ltbr and lrrc15
Min The Development of Antibody-Based Therapeutics Against Lymphocyte Antigen 6K (LY6K) for Human Malignancies
HK40112237A (zh) 双特异性抗ccl2抗体
CN119552247A (zh) 抗cd25抗体及其医药用途
TW202511294A (zh) 介白素-13受體次單元α-2結合劑及其用途
KR20250154601A (ko) Nkg2a와 pd-l1에 결합하는 작용제 및 이의 용도

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000